Home The Word Brain My Amedeo FAQ Privacy About   


Explore this week’s CC Journal Club

90‑sec video • 4‑min audio • paper abstracts


  HIV Infection

  Free Subscription


31.03.2025

1 AIDS
5 Clin Infect Dis
3 HIV Med
3 J Acquir Immune Defic Syndr
1 J Clin Invest
1 J Immunol
2 J Infect Dis
1 J Med Virol
3 J Virol
1 Lancet Infect Dis
1 Nat Med
9 PLoS One
2 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AIDS

  1. DUARTE MJ, Tien PC, Kardashian A, Ma Y, et al
    Microbial translocation and gut damage is associated with hepatic fibrosis but not steatosis in women with and without HIV.
    AIDS. 2025 Mar 25. doi: 10.1097/QAD.0000000000004189.
    PubMed         Abstract available


    Clin Infect Dis

  2. PEREZ-VALERO I, Mata DC, Espejo AC, Gallo M, et al
    Real-world effectiveness and safety of BIC/FTC/TAF in comparison with other regimens in people with HIV starting therapy with AIDS-defining conditions. Results from the CORIS Cohort: The ACTUAS II Study.
    Clin Infect Dis. 2025 Mar 27:ciaf162. doi: 10.1093.
    PubMed         Abstract available

  3. BARTL L, Zeeb M, Kalin M, Loosli T, et al
    Machine Learning-Based Prediction of Active Tuberculosis in People with HIV using Clinical Data.
    Clin Infect Dis. 2025 Mar 25:ciaf149. doi: 10.1093.
    PubMed         Abstract available

  4. ADZEMOVIC T, Nalintya E, Fieberg A, Mande E, et al
    Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease.
    Clin Infect Dis. 2025 Mar 25:ciaf079. doi: 10.1093.
    PubMed         Abstract available

  5. MEYEROWITZ EA, Schwartz IS
    Silence=Death Redux: Infectious Diseases, Public Health, and the Imperative to Resist.
    Clin Infect Dis. 2025 Mar 24:ciaf155. doi: 10.1093.
    PubMed         Abstract available

  6. CUELLA-MARTIN I, Hakizayezu F, Ahmed A, Runyambo D, et al
    Paucibacillary tuberculosis drives the low positive predictive value of Xpert MTB/RIF Ultra for rifampicin resistance detection in low-prevalence settings.
    Clin Infect Dis. 2025 Mar 22:ciaf132. doi: 10.1093.
    PubMed         Abstract available


    HIV Med

  7. MOSHI LS, Okuma J, Luoga E, Kalinjuma AV, et al
    Trends of severe HIV disease and mortality among children in rural Tanzania.
    HIV Med. 2025 Mar 25. doi: 10.1111/hiv.70015.
    PubMed         Abstract available

  8. SAUMOY M, Fernandez A, Tiraboschi J, Penafiel J, et al
    Biomarkers of inflammation and coagulation predict non-AIDS-defining events in a prospective cohort of virologically suppressed people living with HIV.
    HIV Med. 2025 Mar 25. doi: 10.1111/hiv.70017.
    PubMed         Abstract available

  9. VASELLI NM, Salaveria K, Winearls J, Garnham K, et al
    Pneumocystis jirovecii pneumonia-Immune reconstitution inflammatory syndrome: A review of published cases.
    HIV Med. 2025 Mar 24. doi: 10.1111/hiv.70016.
    PubMed         Abstract available


    J Acquir Immune Defic Syndr

  10. KIPTINNESS C, Mugo N, Mugwanya KK, Ngure K, et al
    THE EFFECT OF PARTNER DELIVERY OF HIV SELF-TEST KITS ON HIV TESTING AND LINKAGE TO CARE IN PUBLIC CLINICS IN KENYA.
    J Acquir Immune Defic Syndr. 2025 Mar 26. doi: 10.1097/QAI.0000000000003662.
    PubMed         Abstract available

  11. BANGA J, Nelson BS, Ajibola G, Mohammed T, et al
    Predictive markers for sustained viral suppression on dual bNAbs during ART interruption in children.
    J Acquir Immune Defic Syndr. 2025 Mar 26. doi: 10.1097/QAI.0000000000003663.
    PubMed         Abstract available

  12. BUTTS SA, Johnson AL, Doblecki-Lewis S
    PrEP Beyond the Clinic: Evaluation of a Home-Based PrEP Follow-Up System Among a Cohort of Predominantly Black and Latino Men who Have Sex with Men in South Florida.
    J Acquir Immune Defic Syndr. 2025 Mar 28. doi: 10.1097/QAI.0000000000003664.
    PubMed         Abstract available


    J Clin Invest

  13. MACLEAN F, Tsegaye AT, Graham JB, Swarts JL, et al
    Bacterial vaginosis associates with dysfunctional T cells and altered soluble immune factors in the cervicovaginal tract.
    J Clin Invest. 2025 Mar 25:e184609. doi: 10.1172/JCI184609.
    PubMed         Abstract available


    J Immunol

  14. LACOMBE RV, Lorin V, Planchais C, Lassouani TH, et al
    HIV-1 broadly neutralizing antibodies demonstrate a high propensity for binding to heme.
    J Immunol. 2025 Mar 22:vkaf015. doi: 10.1093.
    PubMed         Abstract available


    J Infect Dis

  15. KLASTRUP V, Gunst JD, Rasmussen TA, Tolstrup M, et al
    Factors influencing virologic control during analytical treatment interruptions in HIV cure trials - a pooled analysis of individual level data.
    J Infect Dis. 2025 Mar 26:jiaf163. doi: 10.1093.
    PubMed         Abstract available

  16. TOLEDO JP
    Empowering Futures: Restoring T Cell Responses in Children Living with HIV.
    J Infect Dis. 2025 Mar 26:jiaf160. doi: 10.1093.
    PubMed         Abstract available


    J Med Virol

  17. BETTUZZI T, Lebbe C, Grolleau C
    Modern Approach to Manage Patients With Kaposi Sarcoma.
    J Med Virol. 2025;97:e70294.
    PubMed         Abstract available


    J Virol

  18. VICTORIA S, Leyens J, Meckes LM, Vavouras Syrigos G, et al
    CD4+ T cells facilitate replication of primary HIV-1 strains in macrophages and formation of macrophage internal virus-containing compartments.
    J Virol. 2025 Mar 25:e0018225. doi: 10.1128/jvi.00182.
    PubMed         Abstract available

  19. YAN H, Gao Y, Zhu Y, Chong H, et al
    Addition of a short HIV-1 fusion-inhibitory peptide to PRO 140 antibody dramatically increases its antiviral breadth and potency.
    J Virol. 2025 Mar 25:e0201824. doi: 10.1128/jvi.02018.
    PubMed         Abstract available

  20. CHATTERJEE D, Niu L, Medjahed H, Ding S, et al
    A gp41 HR2 residue modulates the susceptibility of HIV-1 envelope glycoproteins to small molecule inhibitors targeting gp120.
    J Virol. 2025 Mar 27:e0226724. doi: 10.1128/jvi.02267.
    PubMed         Abstract available


    Lancet Infect Dis

  21. MCCLURE M, Gandhi M
    Threat of HIV and tuberculosis drug resistance after US funding cuts.
    Lancet Infect Dis. 2025 Mar 20:S1473-3099(25)00209.
    PubMed        


    Nat Med

  22. PEKAR JE, Wang Y, Wang JC, Shao Y, et al
    Transmission dynamics of the 2022 mpox epidemic in New York City.
    Nat Med. 2025 Mar 25. doi: 10.1038/s41591-025-03526.
    PubMed         Abstract available


    PLoS One

  23. MELKAM M, Fentahun S, Takelle GM, Rtbey G, et al
    Prevalence and determinants of depression and/or anxiety among adults using Kenya Demographic and Health Survey of 2022: Multilevel logistic regression analysis.
    PLoS One. 2025;20:e0319571.
    PubMed         Abstract available

  24. WHITE DAE, Jewett M, Burns M, Rodriguez C, et al
    A quality improvement initiative to increase HIV post-exposure prophylaxis treatment for emergency department patients after sexual assault: A pre-post study.
    PLoS One. 2025;20:e0320690.
    PubMed         Abstract available

  25. CROOKS N, Donenberg G, Ogwumike J, Silva J, et al
    A randomized controlled trial of a family-based HIV/STI prevention program for Black girls and male caregivers in Chicago: IMAGE study protocol paper.
    PLoS One. 2025;20:e0320164.
    PubMed         Abstract available

  26. ARANT EC, Kavee AL, Wheeler B, Shook-Sa BE, et al
    A novel use of HIV surveillance and court data to understand and improve care among a population of people with HIV experiencing criminal charges in North Carolina 2017-2020.
    PLoS One. 2025;20:e0302767.
    PubMed         Abstract available

  27. AGIMAS MC, Tesfie TK, Derseh NM, Kassaw A, et al
    Derivation and validation of a model to predict treatment failure among under five children with severe community acquired pneumonia who are admitted at Debre Tabor specialized comprehensive hospital.
    PLoS One. 2025;20:e0320448.
    PubMed         Abstract available

  28. GRONNINGEN E, Nanyaro M, Ngadaya E, Mustafa T, et al
    Diagnostic and treatment delay in extrapulmonary tuberculosis and association with mortality: Experiences from Mbeya, Tanzania.
    PLoS One. 2025;20:e0320691.
    PubMed         Abstract available

  29. SINCLAIR P, Jeffries W, Lebert N, Saeed M, et al
    A predictive machine learning model for cannabinoid effect based on image detection of reactive oxygen species in microglia.
    PLoS One. 2025;20:e0320219.
    PubMed         Abstract available

  30. WATSON DL, Bonett S, Meanley S, Wood SM, et al
    Acceptability and feasibility of HIV self-testing integration into publicly-funded HIV prevention services: Perspectives from HIV testing agency staff that provide HIV testing services to sexual and gender minority youth in Philadelphia County.
    PLoS One. 2025;20:e0320290.
    PubMed         Abstract available

  31. MUKUKU O, Govender K, Wembonyama SO
    Barriers and facilitators to HIV viral load suppression among adolescents living with HIV in Lubumbashi, Democratic Republic of the Congo: A qualitative study.
    PLoS One. 2025;20:e0320417.
    PubMed         Abstract available


    Vaccine

  32. KANG M, Marks KM, Cox AL, Sherman KE, et al
    An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.
    Vaccine. 2025;55:127028.
    PubMed         Abstract available

  33. EMARY K, Bentsi-Enchill AD, Giersing BK, Gordon M, et al
    Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation.
    Vaccine. 2025;55:127008.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.